Century Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Century Therapeutics, Inc. - overview
Established
2018
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Founded in 2018 and based in Pennsylvania, US, Century Therapeutics, Inc. operates as a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology. In March 2020, Century Therapeutics raised USD 160 million in Series C funding led by Casdin Capital. The company has 107 employees as of April 2021.
In June 2021, Century Therapeutics, Inc. raised USD 211 million in IPO, selling 10. 6 million shares at USD 20 per share on the NASDAQ. It trades on NASDAQ under the ticker symbol IPSC.
Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer. The company's genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. The company plans to use its Series C funding to help the pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products. These products are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients.
Current Investors
Versant Ventures, Bayer AG, Cellular Dynamics International, Inc.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.centurytx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Century Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Century Therapeutics, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.